Towards understandings of serine/arginine-rich splicing factors  

作　　者：Dianyang Li Wenying Yu Maode Lai 

机构地区：[1]School of Basic Medicine and Clinical Pharmacy,China Pharmaceutical University,Nanjing 210009,China [2]State Key Laboratory of Natural Medicines,China Pharmaceutical University,Nanjing 210009,China [3]Department of Pathology,Research Unit of Intelligence Classification of Tumor Pathology and Precision Therapy,Chinese Academy of Medical Science(2019RU042),Key Laboratory of Disease Proteomics of Zhejiang Province,Zhejiang University School of Medicine,Hangzhou 310058,China

出　　处：《Acta Pharmaceutica Sinica B》2023年第8期3181-3207,共27页药学学报（英文版）

基　　金：supported by grants from the National Natural Science Foundation of China(Grant No.82150203)。

摘　　要：Serine/arginine-rich splicing factors(SRSFs)refer to twelve RNA-binding proteins which regulate splice site recognition and spliceosome assembly during precursor messenger RNA splicing.SRSFs also participate in other RNA metabolic events,such as transcription,translation and nonsensemediated decay,during their shuttling between nucleus and cytoplasm,making them indispensable for genome diversity and cellular activity.Of note,aberrant SRSF expression and/or mutations elicit fallacies in gene splicing,leading to the generation of pathogenic gene and protein isoforms,which highlights the therapeutic potential of targeting SRSF to treat diseases.In this review,we updated current understanding of SRSF structures and functions in RNA metabolism.Next,we analyzed SRSF-induced aberrant gene expression and their pathogenic outcomes in cancers and non-tumor diseases.The development of some well-characterized SRSF inhibitors was discussed in detail.We hope this review will contribute to future studies of SRSF functions and drug development targeting SRSFs.

关 键 词：Alternative splicing RNA metabolism Cancer therapy TAUOPATHY Autoimmunediseases Small molecule inhibitor 

分 类 号：R73[医药卫生—肿瘤]